Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugemalimab, Olaparib, Chemotherapy and LDRT in First-Line SLFN-11 Positive ES-SCLC
NCT06217757Phase 2Recruiting
- Sponsor
- Sichuan University
- Start
- Apr 2024
- Primary completion
- Oct 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sugemalimab, olaparib in small cell lung cancer (SCLC), sponsored by Sichuan University. Started Apr 2024; status: recruiting.
02
Drugs
sugemalimabolaparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06217757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06217757.